5. Concluding Comments
This chapter outlined the authors’ current perspective on the complexities of general product testing requirements and design characteristics for preclinical studies involved in investigational use of cellular products for cardiac repair. The IND process is intended to balance the potential benefit of novel therapies to society with the need to generate data for prudent product development, to increase scientific knowledge, to protect subject safety, and to benefit the public health. This chapter represents an introduction to the regulation of these cellular products and investigator/sponsors are encouraged to contact FDA CBER OCTGT for more specific information on the conduct of clinical trials.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
6. References
Orlic D, Hill JM, Arai AE. Stem cells for myocardial regeneration. Circ Res. 2002 Dec 13;91(12):1092–102
Wognum AW, Eaves AC, Thomas TE. Identification and isolation of hematopoietic stem cells. Arch Med Res. 2003 Nov–Dec;34(6):461–75.
Rehman J, Li J, Orschell CM, March KL. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003 Mar 4;107(8):1164–9.
Hirata Y, Sata M, Motomura N, Takanashi M, Suematsu Y, Ono M, Takamoto S. Human umbilical cord blood cells improve cardiac function after myocardial infarction. Biochem Biophys Res Commun. 2005 Feb 11;327(2):609–14.
Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H, Onitsuka I, Matsui K, Imaizumi T. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest. 2000 Jun;105(11):1527–36.
Schmeisser A, Garlichs CD, Zhang H, Eskafi S, Graffy C, Ludwig J, Strasser RH, Daniel WG. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res. 2001 Feb 16;49(3):671–80.
Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22(3):377–84.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143–7.
Hassink RJ, Brutel de la Riviere A, Mummery CL, Doevendans PA. Transplantation of cells for cardiac repair. J Am Coll Cardiol. 2003 Mar 5;41(5):711–7.
Gunsilius E, Gastl G, Petzer AL. Hematopoietic stem cells. Biomed Pharmacother. 2001 May;55(4):186–94.
Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R, Waksman R, Weissman NJ, Cerqueira M, Leon MB, Epstein SE. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol. 2003 May 21;41(10):1721–4.
Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, Dinsmore JH, Wright S, Aretz TH, Eisen HJ, Aaronson KD. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol. 2003 Mar 5;41(5):879–88
Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003 Sep 19;114(6):763–76.
Miranville A, Heeschen C, Sengenes C, Curat CA, Busse R, Bouloumie A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation. 2004 Jul 20;110(3):349–55. Epub 2004 Jul 06.
Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001 Apr;7(2):211–28.
US Food and Drug Administration. Transcripts of the meeting of the Biological Response Modifiers Advisory Committee: Discussion of Cellular Therapies of Cardiac Disease. 18–19 March 2004. Available at http://www.fda.gov/ohrms/dockets/ac/cber04.html#BiologicalResponseModifiers
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Areman, E., Benton, K., Mcfarland, R. (2006). Regulatory Considerations in Manufacturing, Product Testing, and Preclinical Development of Cellular Products for Cardiac Repair. In: Dib, N., Taylor, D.A., Diethrich, E.B. (eds) Stem Cell Therapy and Tissue Engineering for Cardiovascular Repair. Springer, Boston, MA. https://doi.org/10.1007/0-387-30939-X_20
Download citation
DOI: https://doi.org/10.1007/0-387-30939-X_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25788-4
Online ISBN: 978-0-387-30939-2
eBook Packages: EngineeringEngineering (R0)